Mojca Jongen-Lavrencic
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.
Hilberink J, van Zeventer I, Chitu D, Pabst T, Klein S, Stussi G, Griskevicius L, Valk P, Cloos J, van de Loosdrecht A, Breems D, van Lammeren-Venema D, Boersma R, Jongen-Lavrencic M, Fehr M, Hoogendoorn M, Manz M, Söhne M, van Marwijk Kooy R, Deeren D, van der Poel M, Legdeur M, Tick L, Chalandon Y, Ammatuna E, Blum S, Löwenberg B, Ossenkoppele G, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Huls G. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine. Blood Cancer J 2023; 13:93.
Jun 19, 2023Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.
Jun 19, 2023Blood Cancer J 2023; 13:93
Hilberink Jacobien R, van Zeventer Isabelle A, Chitu Dana A, Pabst Thomas, Klein Saskia K, Stussi Georg, Griskevicius Laimonas, Valk Peter J M, Cloos Jacqueline, van de Loosdrecht Arjan A, Breems Dimitri A, van Lammeren-Venema Daniëlle, Boersma Rinske, Jongen-Lavrencic Mojca, Fehr Martin, Hoogendoorn Mels, Manz Markus G, Söhne Maaike, van Marwijk Kooy Rien, Deeren Dries, van der Poel Marjolein W M, Legdeur Marie-Cecile J C, Tick Lidwine W, Chalandon Yves, Ammatuna Emanuele, Blum Sabine, Löwenberg Bob, Ossenkoppele Gert J, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Huls Gerwin
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
Janssen J, Löwenberg B, Manz M, Biemond B, Westerweel P, Klein S, Fehr M, Sinnige H, Efthymiou A, Legdeur M, Pabst T, Gregor M, van der Poel M, Deeren D, Tick L, Jongen-Lavrencic M, van Obbergh F, Boersma R, de Weerdt O, Chalandon Y, Heim D, Spertini O, van Sluis G, Graux C, Stüssi G, van Norden Y, Ossenkoppele G. Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome. Leukemia 2022; 36:2189-2195.
Jul 22, 2022Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
Jul 22, 2022Leukemia 2022; 36:2189-2195
Janssen J J W M, Löwenberg Bob, Manz M, Biemond B J, Westerweel P E, Klein S K, Fehr M, Sinnige H A M, Efthymiou Anna, Legdeur M C J C, Pabst T, Gregor M, van der Poel M W M, Deeren Dries, Tick L W, Jongen-Lavrencic Mojca, van Obbergh F, Boersma R S, de Weerdt Okke, Chalandon Yves, Heim D, Spertini Olivier, van Sluis G, Graux Carlos, Stüssi G, van Norden Y, Ossenkoppele G J
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
Ossenkoppele G, Pabst T, Oosterveld M, Obbergh F, Nijziel M, Moors I, Kooy M, Maertens J, Loosdrecht A, Legdeur M, Poel M, Sinnige H, Spertini O, Norden Y, Stussi G, Westerweel P, Weerdt O, Vellenga E, Vekemans M, Velden W, Tick L, Terpstra W, Lammeren-Venema D, Kuball J, Deeren D, Chalandon Y, Brouwer R, Breems D, Borne P, Biemond B, Bargetzi M, Manz M, Löwenberg B, Efthymiou A, Gjertsen B, Graux C, Klift M, Klein S, Jongen-Lavrencic M, Jie A, Jaspers A, Hoogendoorn M, Hess U, Heim D, Gregor M, Janssen J. Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers (Basel) 2021; 13
Feb 7, 2021Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
Feb 7, 2021Cancers (Basel) 2021; 13
Ossenkoppele Gert, Pabst Thomas, Oosterveld Margriet, Obbergh Florence van, Nijziel Marten, Moors Ine, Kooy Marinus van Marwijk, Maertens Johan, Loosdrecht Arjan van de, Legdeur Marie-Cecile, Poel Marjolein van der, Sinnige Harm, Spertini Olivier, Norden Yvette van, Stussi Georg, Westerweel Peter, Weerdt Okke de, Vellenga Edo, Vekemans Marie-Christiane, Velden Walter van der, Tick Lidwine, Terpstra Wim, Lammeren-Venema Danielle van, Kuball Jurgen, Deeren Dries, Chalandon Yves, Brouwer Rolf, Breems Dimitri, Borne Peter von dem, Biemond Bart, Bargetzi Mario, Manz Markus, Löwenberg Bob, Efthymiou Anna, Gjertsen Bjørn-Tore, Graux Carlos, Klift Marjolein van der, Klein Saskia, Jongen-Lavrencic Mojca, Jie Asiong, Jaspers Aurelie, Hoogendoorn Mels, Hess Urs, Heim Dominik, Gregor Michael, Janssen Jeroen
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Ossenkoppele G, Porkka K, Cornelissen J, Kuball J, Fischer T, Legdeur M, Hoogendoorn M, Breems D, Moors I, van Lammeren-Venema D, Silzle T, Juliusson G, Meyer P, Floisand Y, Manz M, van Elssen C, Valk P, Cloos J, Passweg J, Huls G, Janssen J, Gjertsen B, Höglund M, Gregor M, Veelken H, van Marwijk Kooy M, Jongen-Lavrencic M, Tick L, Griskevicius L, Vellenga E, Spertini O, Biemond B, Gradowska P, Maertens J, Pabst T, Vekemans M, van der Velden W, Westerweel P, Gadisseur A, Klein S, Bargetzi M, van Esser J, de Weerdt O, Deeren D, Graux C, Michaux L, Beverloo B, Löwenberg B. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood Adv 2021; 5:1110-1121.
Jan 23, 2021Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Jan 23, 2021Blood Adv 2021; 5:1110-1121
Ossenkoppele Gert J, Porkka Kimmo, Cornelissen Jan, Kuball Juergen, Fischer Thomas, Legdeur Marie-Cecile J C, Hoogendoorn Mels, Breems Dimitri A, Moors Ine, van Lammeren-Venema Daniëlle, Silzle Tobias, Juliusson Gunnar, Meyer Peter, Floisand Yngvar, Manz Markus G, van Elssen Catharina H M J, Valk Peter J M, Cloos Jacqueline, Passweg Jakob, Huls Gerwin, Janssen Jeroen J W M, Gjertsen Bjorn T, Höglund Martin, Gregor Michael, Veelken Hendrik, van Marwijk Kooy Marinus, Jongen-Lavrencic Mojca, Tick Lidwine W, Griskevicius Laimonas, Vellenga Edo, Spertini Olivier, Biemond Bart J, Gradowska Patrycja, Maertens Johan, Pabst Thomas, Vekemans Marie-Christiane, van der Velden Walter J F M, Westerweel Peter E, Gadisseur Alain, Klein Saskia K, Bargetzi Mario, van Esser Joost W J, de Weerdt Okke, Deeren Dries, Graux Carlos, Michaux Lucienne, Beverloo Berna, Löwenberg Bob